{
  "nctId": "NCT04490239",
  "briefTitle": "Intranasal Heparin Tolerability Study",
  "officialTitle": "Intranasal Heparin Tolerability Study",
  "protocolDocument": {
    "nctId": "NCT04490239",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2020-09-01",
    "uploadDate": "2020-12-15T09:39",
    "size": 1271337,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT04490239/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "EARLY_PHASE1"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NA",
  "interventionModel": "SEQUENTIAL",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 6,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2020-10-09",
    "completionDate": "2020-11-18",
    "primaryCompletionDate": "2020-11-18",
    "firstSubmitDate": "2020-07-20",
    "firstPostDate": "2020-07-29"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\nNormal, healthy adults aged 18 to 65 years\n\nExclusion Criteria:\n\n* Allergy to Heparin\n* Currently taking any prescription blood thinners or anti-coagulants, or currently taking any intranasal medication\n* Known history of anemia, thrombocytopenia, or other blood disorder\n* Autoimmune disorders\n* Known history of Neurologic/Psychiatric disorders\n* Report of an active infection\n* Subject is pregnant or breast-feeding, or is expecting to conceive during the study.\n\nNOTE: Subjects will be instructed to abstain from alcohol for the duration of the study.",
    "healthyVolunteers": true,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "65 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Number of Participants With Normal or Abnormal Activated Partial Thromboplastin Time (aPTT), Acute Phase Day 1",
        "description": "A measurement of blood clotting ability; tests for systemic bioavailability of intranasal heparin collected 24 hours after a 1000 U intranasal dose of heparin",
        "timeFrame": "24 hours after a 1000 U intranasal dose of heparin"
      },
      {
        "measure": "Number of Participants With Normal or Abnormal Activated Partial Thromboplastin Time (aPTT), Acute Phase Day 2",
        "description": "A measurement of blood clotting ability; tests for systemic bioavailability of intranasal heparin collected 24 hours after a 2000 U intranasal dose of heparin",
        "timeFrame": "24 hours after 2000 U dose intranasal heparin"
      },
      {
        "measure": "Number of Participants With Normal or Abnormal Activated Partial Thromboplastin Time (aPTT), Chronic Phase Day 14",
        "description": "A measurement of blood clotting ability; tests for systemic bioavailability of intranasal heparin obtained immediately after the 14 consecutive day of daily 2000 U dose of intranasal heparin",
        "timeFrame": "Day 14, chronic phase"
      },
      {
        "measure": "Number of Participants With Normal or Abnormal Activated Partial Thromboplastin Time (aPTT), Chronic Phase Day 15",
        "description": "A measurement of blood clotting ability; tests for systemic bioavailability of intranasal heparin obtained 24 hours after the 14 consecutive day of daily 2000 U dose of intranasal heparin",
        "timeFrame": "24 hours after the last 2000 U dose of the chronic phase"
      },
      {
        "measure": "Percent Change in Platelet Count From Pre-dose Baseline",
        "description": "Indicative of heparin-induced thrombocytopenia, a serious adverse side effect of systemically bioavailable heparin, measured immediately after the last 2000 U intranasal dose of the chronic phase.",
        "timeFrame": "Pre-dose baseline, Day 14 chronic phase"
      },
      {
        "measure": "Number of Incidents of Epistaxis, Acute Phase",
        "description": "Number of incidents of blood coming from the nose during the acute phase",
        "timeFrame": "Day 0 through Day 2, acute phase"
      },
      {
        "measure": "Number of Incidents of Epistaxis, Chronic Phase",
        "description": "Blood coming from the nose or pink tinged nasal secretions",
        "timeFrame": "Day 1 through Day 15, chronic phase"
      },
      {
        "measure": "Number of Participants With Normal or Abnormal Platelet Counts, Chronic Phase Day 14",
        "description": "Abnormally low platelet counts indicative of heparin-induced thrombocytopenia, a serious adverse side effect of systemically bioavailable heparin, measured immediately after the last 2000 U intranasal dose of the chronic phase.",
        "timeFrame": "Day 14, Chronic Phase"
      }
    ],
    "secondary": [
      {
        "measure": "Other Adverse Effects, Acute Phase",
        "description": "Reports of mild, short-lived nasal irritation immediately after administration including mild burning sensation",
        "timeFrame": "Day 0 through Day 2, acute phase"
      },
      {
        "measure": "Other Adverse Effects, Chronic Phase",
        "description": "Reports of mild, short-lived nasal irritation immediately after administration including mild burning sensation, itchiness or sneezing",
        "timeFrame": "Day 1 through Day 15, chronic phase"
      }
    ],
    "other": []
  },
  "realComplexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 7,
      "totalCount": 8
    },
    "endpoints": {
      "primaryCount": 8,
      "secondaryCount": 2,
      "otherCount": 0,
      "totalCount": 10
    },
    "studyDesign": {
      "phases": [
        "EARLY_PHASE1"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "SEQUENTIAL"
    },
    "overallComplexityScore": 100,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-21T22:32:18.732Z",
  "dataSource": "ClinicalTrials.gov API v2"
}